NeuroPace Inc Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||
2024 | 2023 | ||||||||||
| Numerator: | |||||||||||
| Net loss attributable to common stockholders | $ | (27,141) | $ | (32,956) | |||||||
| Denominator: | |||||||||||
| Weighted-average common stock outstanding used to compute basic and diluted net loss per share | 29,126,314 | 25,851,813 | |||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.93) | $ | (1.27) | |||||||
December 31, | |||||||||||
2024 | 2023 | ||||||||||
| Options to purchase common stock | 2,368,208 | 2,588,765 | |||||||||
| Unvested restricted stock units | 1,480,338 | 2,430,803 | |||||||||
| Shares committed under ESPP | 68,138 | 81,102 | |||||||||
| Unvested early exercised common stock options | — | 30,211 | |||||||||
| Total Shares | 3,916,684 | 5,130,881 | |||||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.